(Q36438737)

14 August 2017

1 reference

title

Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy (English)

1 reference

14 August 2017

1 reference

Scott M Grundy

1

1 reference

14 August 2017

publication date

1 April 2006

1 reference

Nature Reviews Drug Discovery

14 August 2017

published in

1 reference

14 August 2017

volume

5

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

295-309

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2005

14 August 2017

exact match

0 references

cites work

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

21 January 2018

The metabolic syndrome

1 reference

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

21 January 2018

1 reference

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

21 January 2018

1 reference

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

21 January 2018

1 reference

Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

21 January 2018

1 reference

High prevalence of metabolic syndrome among young women with premature coronary artery disease

21 January 2018

1 reference

Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?

21 January 2018

1 reference

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

The metabolically obese, normal-weight individual revisited

21 January 2018

1 reference

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist

21 January 2018

1 reference

Adipose tissue, inflammation, and cardiovascular disease

21 January 2018

1 reference

Adipocytokines and metabolic syndrome

21 January 2018

1 reference

Adipokines: inflammation and the pleiotropic role of white adipose tissue

21 January 2018

1 reference

Keynote review: the adipocyte as a drug discovery target

21 January 2018

1 reference

The efficacy and safety of sibutramine for weight loss: a systematic review

21 January 2018

1 reference

Endocannabinoid control of food intake and energy balance

21 January 2018

1 reference

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

21 January 2018

1 reference

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

21 January 2018

1 reference

Orlistat: a review of its use in the management of patients with obesity

21 January 2018

1 reference

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

21 January 2018

1 reference

Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis

21 January 2018

1 reference

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

21 January 2018

1 reference

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

21 January 2018

1 reference

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

21 January 2018

1 reference

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

21 January 2018

1 reference

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

21 January 2018

1 reference

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

21 January 2018

1 reference

Therapeutic roles of peroxisome proliferator-activated receptor agonists

21 January 2018

1 reference

Regulation of lipid and lipoprotein metabolism by PPAR activators

21 January 2018

1 reference

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

21 January 2018

1 reference

Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis

21 January 2018

1 reference

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

21 January 2018

1 reference

PPARalpha activators inhibit tissue factor expression and activity in human monocytes

21 January 2018

1 reference

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages

21 January 2018

1 reference

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

HDL as a target in the treatment of atherosclerotic cardiovascular disease

21 January 2018

1 reference

Pharmacotherapy for dyslipidaemia – current therapies and future agents

21 January 2018

1 reference

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients

21 January 2018

1 reference

Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid Metabolism

21 January 2018

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

Antihypertensive treatment of patients with diabetes and hypertension

21 January 2018

1 reference

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

21 January 2018

1 reference

Should angiotensin II receptor blockers and statins be combined?

21 January 2018

1 reference

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis

21 January 2018

1 reference

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

21 January 2018

1 reference

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

Increasing prevalence of the metabolic syndrome among u.s. Adults.

21 January 2018

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus

21 January 2018

1 reference

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).

21 January 2018

1 reference

Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists

21 January 2018

1 reference

PPARgamma and atherosclerosis

21 January 2018

1 reference

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial

21 January 2018

1 reference

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis

21 January 2018

1 reference

Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency

21 January 2018

1 reference

A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity

21 January 2018

1 reference

Peroxisome Proliferator-Activated Receptors and the Control of Inflammation

21 January 2018

1 reference

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

21 January 2018

1 reference

Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells

21 January 2018

1 reference

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

21 January 2018

1 reference

Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation

21 January 2018

1 reference

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious gluco

21 January 2018

1 reference

A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia

21 January 2018

1 reference

Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity

21 January 2018

1 reference

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)

21 January 2018

1 reference

Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer

21 January 2018

1 reference

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

PPARs and the complex journey to obesity

21 January 2018

1 reference

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

21 January 2018

1 reference

Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta

21 January 2018

1 reference

The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells

21 January 2018

1 reference

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

21 January 2018

1 reference

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

21 January 2018

1 reference

Follow-up report on the diagnosis of diabetes mellitus

21 January 2018

1 reference

The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities

21 January 2018

1 reference

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome

21 January 2018

1 reference

Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice

21 January 2018

1 reference

Coagulation and fibrinolysis abnormalities in obesity

21 January 2018

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease

21 January 2018

1 reference

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

21 January 2018

1 reference

The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm

21 January 2018

1 reference

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

21 January 2018

1 reference

Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management

31 March 2020

1 reference

Cardiovascular morbidity and mortality associated with the metabolic syndrome

31 March 2020

1 reference

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

31 March 2020

1 reference

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

31 March 2020

1 reference

Connecting the role of C-reactive protein and statins in cardiovascular disease

31 March 2020

1 reference

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

31 March 2020

1 reference

High-density lipoprotein and coronary heart disease: lessons from recent intervention trials

31 March 2020

1 reference

Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2005

1 reference

14 August 2017

1 reference